Calypte notified of possible Amex delisting

Calypte Biomedical (Lake Oswego, Oregon) reported that on Feb. 14, the American Stock Exchange notified the company that it had set March 13 as the date for a hearing to review the Amex staff's determination to delist the company's common stock from trading on Amex.

Calypte had requested a hearing by a listing qualifications panel to appeal the staff's determination by letter dated Feb. 9. If its common stock is delisted from the exchange after the hearing, the company said it would likely trade on the NASD Over-the-Counter Bulletin Board.

Calypte Biomedical is developing diagnostic testing products for the detection of sexually transmitted diseases.

No Comments